# Immunogenicity, Safety and Tolerability of CSL Limited Inactivated Influenza Vaccine in Adults

> **NCT00333398** · PHASE3 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 1359 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** CSL Trivalent Inactivated Influenza Vaccine - Thimerosal-free
- **BIOLOGICAL:** CSL Trivalent Inactivated Influenza Vaccine with Thimerosal
- **BIOLOGICAL:** Placebo with Thimerosal

## Key facts

- **NCT ID:** NCT00333398
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2006-08
- **Final completion:** 2006-08
- **Target enrollment:** 1359 (ACTUAL)
- **Last updated:** 2010-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00333398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00333398, "Immunogenicity, Safety and Tolerability of CSL Limited Inactivated Influenza Vaccine in Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00333398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*